On September 20, 2021, leading medical experts presented their latest insights on nerve and muscle biomarkers in SMA and ALS. Here's a recap of Biogen's symposium.
Share page
Biomarkers of nerve and muscle changes in SMA and ALS
Our expert Faculty discussed the potential roles of biomarkers of nerve damage (neurofilaments), energy storage and metabolism within muscles and disease specific biomarkers in clinical practice. Learn more about the speakers and what they discussed at the symposium, and find links to more information.
Meet the faculty
Facilitator
and Q&A
Matthew Kiernan
NM, MBBS, PhD, DSc, FRACP, FAHMS (Chair)
University of Sydney and Royal Prince Alfred Hospital, Sydney, NSW, Australia
Disease-specific
biomarkers and
neurofilaments in ALS
Charlotte Sumner
MD
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Disease-specific
biomarkers and
neurofilaments in SMA
Philip Van Damme
MD, PhD
University Hospitals Leuven, Leuven, Belgium
“Serum creatine kinase and
creatinine in adult spinal
muscular atrophy”
René Günther
Dr. Med.
Technische Universität Dresden (TUD), Dresden, Germany
More Resources about SMA and ALS for Healthcare Professionals
As noted at Biogen’s WMS symposium, biology and genetics have significant implications for the clinical practices around SMA.
For more about ALS, visit Biogen's website, insideALS: A resource for EU healthcare professionals interested in learning more about the rapidly changing science of ALS, featuring content co-created with key medical experts in the field.
1. Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80(1):155-165.
2. Medline Plus. Genetics Home Reference. SMN1. [online] 2016 Apr 20 [cited 2020 Sept 30]. Available from: URL: https://ghr.nlm.nih.gov/gene/SMN1.
